Compare Boston Beer Company Inc (SAM) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Beer Company Inc vs Smith & Nephew plc — how do they compare? Boston Beer Company Inc trades at $170.75 (market cap $1.88B), while Smith & Nephew plc trades at $30.45 (market cap $12.64B). The key difference: Smith & Nephew plc is far larger — about 6.7× Boston Beer Company Inc's market cap, and Smith & Nephew plc pays a 2.57% dividend while Boston Beer Company Inc pays none. Which is the better fit depends on your goals.
| SAM | SNN | |
|---|---|---|
Market Cap | $1.88B | $12.64B |
Sector | Consumer Staples | Health |
52-Week High | $260.05 | $38.70 |
52-Week Low | $161.08 | $28.73 |
Enterprise Value | $1.75B | $15.41B |
Dividend Yield | — | 2.57% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
